LCTX · Lineage Cell Therapeutics, Inc.
$1.08
-0.02 (-1.82%)
At close · Sep 4
View the 10-K filed Mar 5, 2026
Customer concentration
— top 2 customers 92% of revenue
2 customers — 92% of revenue (the year ended December 31, 2025)
“For the year ended December 31, 2025, the Company’s top two customers collectively represented 92% of the Company’s total revenue.”
One customer — 92% of revenue (the year ended December 31, 2024)
“For the year ended December 31, 2024, the Company's top single customer represented 92% of the Company’s total revenue.”
Market Cap
$273.14M
Shares
252.91M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$14.56M
+53.2%
FY2025
Net Income
-$63.53M
-241.4%
FY2025
Gross Margin
92.5%
-2.6pp
FY2023
Operating Margin
-251.57%
-25.5pp
FY2025
Diluted EPS
-$0.28
-211.1%
FY2025
Operating Cash Flow
-$18.92M
+18.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $13.08M | $14.56M | $9.5M | $8.95M | $14.7M | $4.34M | $1.83M | $3.52M | $4.99M | $3.46M | $5.92M | $7.04M | $5.24M | $4.43M | $3.92M | $4.43M | $3.71M | $1.93M | |
| $1.62M | — | — | — | $829K | $2000 | $1.04M | — | — | — | — | -$640K | -$89K | $0 | $19.38K | $29.73K | -$124.3K | -$1.65M | |
| $272K | — | $334K | $671K | $728K | $1.43M | $385K | $412K | $302K | $168K | $358K | $1.11M | $837K | $793K | $434.27K | $79.4K | $27.72K | — | |
| — | — | — | $8.27M | $13.98M | $2.92M | $1.44M | $3.1M | $4.69M | $3.29M | $5.57M | $5.93M | $4.41M | $3.64M | $3.48M | $4.35M | $3.68M | — | |
| — | — | — | 92.5% | 95.05% | 67.15% | 78.92% | 88.28% | 93.95% | 95.14% | 93.96% | 84.27% | 84.04% | 82.12% | 88.91% | 98.21% | 99.25% | — | |
| $20.52M | $17.73M | $12.47M | $15.71M | $13.99M | $33.91M | $12.32M | $17.95M | $20.96M | $24.02M | $36.11M | $42.6M | $37.53M | $26.61M | $18.12M | $13.7M | $8.19M | -$3.18M | |
| $19.35M | $18.46M | $18.17M | $17.3M | $22.51M | $18.21M | $15.57M | $24.03M | $24.73M | $19.92M | $28.43M | $29.13M | $17.56M | $15.56M | $10.37M | $9.34M | $5.34M | -$2.26M | |
| — | $0 | $22K | $130K | $145K | $210K | $1.22M | $2M | $2.19M | $2.35M | $3.58M | $5.26M | $7.36M | $3.3M | $2.45M | $1.99M | $790.12K | $0 | |
| $739K | $699K | $587K | $562K | $582K | $663K | $823K | $1M | $1.08M | $947K | $1.18M | $1.08M | $1.05M | — | — | — | — | — | |
| — | — | — | $33.01M | $36.5M | $52.13M | $27.89M | $41.98M | $46.48M | $43.95M | $64.53M | $71.74M | $55.09M | $59.63M | $28.48M | $23.04M | $13.53M | $5.45M | |
| $39.93M | $51.18M | $30.98M | $33.68M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$26.85M | -$36.62M | -$21.48M | -$24.73M | -$22.52M | -$49.21M | -$26.45M | -$38.88M | -$41.8M | -$38.9M | -$58.97M | -$65.81M | -$50.68M | -$55.99M | -$25M | -$18.69M | -$9.85M | -$3.52M | |
| — | -251.57% | -226.11% | -276.5% | -153.17% | -1133.63% | -1448.36% | -1106% | -837.91% | -1124.99% | -995.56% | -935.32% | -966.48% | -1262.65% | -638.53% | -421.42% | -265.7% | -182.86% | |
| -$26.11M | -$35.92M | -$20.89M | -$24.17M | -$21.94M | -$48.55M | -$25.62M | -$37.87M | -$40.71M | -$37.96M | -$57.79M | -$64.73M | -$49.63M | — | — | — | — | — | |
| -$10.54M | -$32.03M | $2.9M | $1.45M | -$3.29M | $5.94M | $4.52M | $19.64M | -$5.34M | $15.61M | $77.59M | $3.16M | -$473K | -$204K | -$305.18K | $242.55K | -$2.34M | -$1.62M | |
| -$4.44M | — | — | — | — | — | — | — | — | — | -$4.67M | -$35K | $0 | $0 | — | — | — | — | |
| — | -$68.65M | -$18.58M | -$23.28M | -$25.81M | -$43.27M | -$21.92M | -$19.23M | -$47.13M | -$23.29M | $18.62M | -$62.65M | -$51.16M | -$56.19M | -$25.31M | -$18.44M | — | — | |
| — | -$5.28M | $0 | -$1.8M | $541K | — | -$1.24M | -$7.41M | $346K | — | — | — | — | — | — | — | — | — | |
| -$32.26M | -$63.53M | -$18.61M | -$21.49M | -$26.27M | -$43.02M | -$20.65M | -$11.71M | -$45.99M | -$19.98M | $33.57M | -$46.99M | -$36.41M | -$43.88M | -$21.43M | -$16.52M | -$11.18M | -$5.14M | |
| — | -436.47% | -195.9% | -240.2% | -178.69% | -990.99% | -1130.83% | -333.12% | -922.01% | -577.67% | 566.81% | -667.87% | -694.36% | -989.69% | -547.23% | -372.46% | -301.63% | -267.22% | |
| $155K | $166K | $27K | $7000 | -$80K | -$251K | -$36K | -$118K | -$794K | -$3.31M | -$14.95M | -$11.14M | -$7.37M | -$9.03M | -$3.88M | -$1.93M | -$1M | $590 | |
| — | — | — | — | — | — | — | — | — | -$19.98M | $33.57M | -$47.41M | -$36.5M | -$43.88M | -$21.43M | — | — | — | |
| -$32.64M | -$64.58M | -$18.42M | -$20.98M | -$24.63M | -$44.56M | -$23.64M | -$13.82M | -$44.69M | $22.1M | $18.12M | -$58.56M | -$43.66M | -$52.79M | -$25.24M | — | — | — | |
| USD/shares | -$0.14 | -$0.28 | -$0.09 | -$0.12 | -$0.15 | -$0.26 | — | — | — | -$0.17 | $0.35 | -$0.59 | -$0.55 | — | — | — | — | — |
| USD/shares | -$0.19 | -$0.28 | -$0.09 | -$0.12 | -$0.15 | — | — | — | — | -$0.17 | $0.34 | -$0.59 | -$0.55 | — | — | — | — | — |
| shares | — | 230.12M | 200.19M | 172.66M | 169.79M | 164.5M | 150.04K | 145.53K | 126.9K | 114.48M | 97.32M | 79.71M | 66.47M | 54.23M | 49.21M | 47.05M | 40.27M | — |
| shares | — | 230.12M | 200.19M | 172.66M | 169.79M | 164.5K | 150.04K | 145.53K | 126.9K | 114.48M | 99.55M | 79.71M | 66.47M | 54.23M | 49.21M | 47.05M | 40.27M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.07×
EV/EBIT
—
Peer median 9.87×
P/E (TTM)
—
Peer median 11.13×
Peer medians compare against the 315 similar-size Biotechnology companies (of 537 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Non Us | $2,500,000 | — | — | — | — |
| United States | — | $14,703,000 | $3,895,000 | $1,160,000 | $2,092,000 |
| Foreign | — | — | $446,000 | $666,000 | $1,423,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Collaboration Revenues | $13,609,000 | $8,149,000 | $7,588,000 | $13,367,000 | $1,120,000 | — | — |
| Event-Based Milestones and Other Collaborative Revenue | $7,164,000 | — | — | — | — | — | — |
| Upfront License Fees | $6,445,000 | $8,149,000 | — | $13,367,000 | $452,000 | — | — |
| Royalties, License and Other Revenues | $947,000 | $1,350,000 | $1,357,000 | $1,336,000 | — | — | — |
| Event Based Development Milestones | — | — | — | — | $123,000 | — | — |
| Grant Revenues | — | — | — | — | $445,000 | $1,053,000 | — |
| Reimbursements Cost Sharing Payments | — | — | — | — | $545,000 | — | — |
| Royalties from Product Sales and License Fees | — | — | — | — | — | $773,000 | $1,221,000 |
| Royalties | — | — | — | $1,336,000 | $2,776,000 | $773,000 | — |
| Sale of Research Products and Services | — | — | — | — | — | — | $257,000 |
| Grant | — | — | — | — | — | $1,053,000 | $2,037,000 |
| Royalty | — | — | — | — | $2,776,000 | $773,000 | — |
Key facts
CIK
876343
CUSIP
53566P109
13F (30d)
79 filings
79 filers
Visit website
Investor relations